



Alkyl Amines Chemicals Limited

Reg. Office: 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA
Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail : alkyl@alkylamines.com • Web: www.alkylamines.com



Responsible Care®
OUR COMMITMENT TO SUSTAINABILITY

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2020

(Rs.in Lakhs)
(Except per share data)

Sr. No	Particulars	Quarter ended			Year ended
		Jun 30, 2020	Mar 31, 2020	Jun 30, 2019	Mar 31, 2020
		Unaudited	Audited	Unaudited	Audited
I.	Revenue from Operations	24,515.21	23,476.51	26,623.05	99,287.76
II.	Other Income	118.06	261.93	133.26	701.16
III.	Total Revenue (I+II)	24,633.27	23,738.44	26,756.31	99,988.92
IV.	Expenses				
	Cost of Materials Consumed	10,793.45	11,054.36	13,649.71	47,621.68
	Changes in Inventories of Finished Goods and Work-in-Progress	19.81	(264.15)	1,061.30	827.78
	Employee benefit costs	1,991.69	1,695.74	1,668.96	6,964.15
	Finance Costs	192.35	189.32	363.32	1,025.39
	Depreciation and Amortisation Expense	701.96	720.25	639.94	2,690.98
	Other Expenses	3,972.11	4,232.32	4,327.63	18,172.17
	Total Expenses (IV)	17,671.37	17,627.84	21,710.86	77,302.15
V.	Profit before Exceptional Items and Tax (III-IV)	6,961.90	6,110.60	5,045.45	22,686.77
VI.	Exceptional Items	-	-	-	3,284.16
VII.	Profit before tax (V+VI)	6,961.90	6,110.60	5,045.45	25,970.93
VIII.	Tax Expense :				
	Current Tax	1,545.96	1,453.14	1,499.11	5,403.55
	Deferred Tax	145.34	(266.74)	37.05	(1,030.04)
	Tax adjustments of earlier years	(7.53)	3.42	-	69.30
	Total Tax Expenses	1,683.77	1,189.82	1,536.16	4,442.81
IX.	Net Profit for the Period/Year (VII-VIII)	5,278.13	4,920.78	3,509.29	21,528.12
X.	Other Comprehensive Income/ (Expense)				
	a) Items that will not be reclassified to profit or loss - Remeasurement gain/(losses) on defined benefit	(79.49)	(13.13)	(65.16)	(171.17)
	b) Income tax relating to items that will not be reclassified to profit or loss	17.59	1.82	19.39	40.38
	c) Items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves	53.52	0.86	-	0.80
	d) Income tax relating to items that may be reclassified to profit or loss	(11.84)	(0.19)	-	(0.18)
	Other Comprehensive Income / (Expense) for the period/year (Net of Tax)	(20.22)	(10.64)	(45.77)	(130.17)
XI.	Total Comprehensive Income for the period/year	5,257.91	4,910.14	3,463.52	21,397.95
XII.	Paid up Share Capital	1,019.82	1,019.82	1,019.82	1,019.82
XIII.	Face Value of Share (Rs)	5.00	5.00	5.00	5.00
XIV.	Earnings Per Equity Share				
	Basic (Rs)	25.88	24.13	17.21	105.55
	Diluted (Rs)	25.81	24.06	17.16	105.27

Corporate Office: 207 A, Kakad Chambers, 132, Dr. Annie Besant Road Worli, Mumbai - 400 018. INDIA
Tel.: 91-22-2493 1385, 6748 8200 • Fax: 91-22-2493 0710 • CIN No : L99999MH1979PLC021796.

Notes :

- 1 The above unaudited financial results have been reviewed and recommended by the Audit Committee at their meeting held on August 14, 2020, and approved by the Board of Directors at their meeting on the same date. The Limited Review, as required under Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the Quarter ended June 30, 2020 and they have expressed an unmodified opinion on the same.
- 2 The Company is primarily engaged in the business of "Specialty Chemicals". Accordingly, there are no reportable Segments.
- 3 The Company is continuously monitoring the lockdown situation due to spread of Covid-19 pandemic from mid-March and regularly assesses the impact of pandemic on its business operations and performance. The Company is in the business of manufacture and sale of essential products, being mainly pharmaceutical intermediates and is well positioned to fulfil its existing orders and contracts. The Company has been able to meet all its operational needs and is in a comfortable liquidity position to meet its financial commitments. There is no impact on capital and financial resources of the Company. The assets have not been impacted as a result of the pandemic. The Company continues to abide by the directives and advisories issued by various Government authorities and evaluate the impact of COVID-19 as the situation evolves. While there has not been materially adverse impact of COVID-19 on the Company's business operations so far, it is extremely difficult to assess future impact. The Company expects that the demand for its products from pharmaceuticals sector will continue and, as such, barring unforeseen circumstances there will not be a significant impact of COVID-19 on the operations of the Company.
- 4 Figures for the previous periods have been regrouped and reclassified, wherever necessary.

FOR ALKYL AMINES CHEMICALS LTD.

Sd/-

**YOGESH M.KOTHARI
CHAIRMAN & MANAGING DIRECTOR**

Place : Mumbai
Date : August 14, 2020

